A Blood Test for Biological Age Could Help Predict Dementia Risk Years Before Symptoms

What if your birthday was not the best measure of how old you really are?

Chronological age tells us how many years have passed since birth. But biological age tries to answer a deeper question: how quickly is the body actually ageing on the inside?

That difference matters.

Two people can both be 55 years old, but their bodies may not be ageing at the same pace. One may have the internal biology of someone younger, supported by better cardiovascular health, lower inflammation, stronger metabolism, healthier habits, and fewer accumulated stresses. Another may show signs of accelerated ageing, where cells, tissues, blood chemistry, and organs appear older than expected.

A recent study from researchers at King’s College London suggests that this gap between biological age and chronological age may help predict dementia risk years before symptoms appear.

The study used a blood-based ageing clock called MileAge, which estimates biological age by analyzing metabolites in blood plasma. Metabolites are small molecules produced through everyday biological processes, including energy production, inflammation, fat metabolism, and amino acid activity. Together, they can offer a snapshot of how the body is functioning beneath the surface.

Researchers found that people whose biological age was older than their chronological age had a higher risk of developing dementia, particularly vascular dementia. They also tended to develop dementia at a younger age. When accelerated biological ageing was combined with high genetic risk, such as carrying two copies of the APOE ε4 variant, the risk became even more striking.

This does not mean a simple blood test can diagnose dementia today.

It does not mean everyone should rush to test their “biological age.”

It does not mean dementia can be predicted with certainty.

But it does suggest something important: the future of dementia prevention may involve looking not only at the brain, but at the ageing body as a whole.

What Is Biological Age?

Biological age is an estimate of how old the body appears based on internal biological markers.

Chronological age is fixed. If you are 50, you are 50.

Biological age is more flexible. It may be higher or lower than your chronological age depending on genetics, lifestyle, health conditions, inflammation, cardiovascular function, metabolism, stress, sleep, nutrition, physical activity, and environmental exposures.

This is why two people of the same age can feel very different physically and mentally.

One may have strong energy, healthy blood pressure, good mobility, low inflammation, and sharp cognitive function. Another may have metabolic problems, chronic inflammation, vascular damage, fatigue, or early signs of age-related disease.

Biological ageing clocks try to measure those differences.

Some ageing clocks use DNA methylation.

Some use proteins.

Some use clinical blood markers.

Some use metabolites.

The MileAge clock belongs to this metabolomic category. It looks at chemical fingerprints in the blood that may reflect how the body is ageing internally.

The exciting part is that blood is relatively easy to collect compared with more invasive or expensive tests. That makes blood-based ageing tools potentially useful for large-scale research, prevention trials, and eventually, carefully guided clinical risk assessment.

What Is MileAge?

MileAge is a metabolomic ageing clock.

The name refers to an estimate of ageing based on metabolites, which are small molecules involved in the body’s biological and chemical processes. These molecules can reflect metabolism, inflammation, lipid activity, amino acid balance, and other internal systems connected to ageing and disease.

In simple terms, MileAge compares the age suggested by a person’s blood chemistry with their actual chronological age.

The difference is called MileAge delta.

If someone’s MileAge is lower than their real age, their metabolomic profile appears younger than expected.

If someone’s MileAge is higher than their real age, their body appears biologically older than expected.

That “older than expected” gap is what researchers call accelerated biological ageing.

In this dementia study, that gap was important. People with a higher MileAge delta showed a greater chance of developing dementia over time, especially vascular dementia.

This suggests that the same biological systems involved in ageing, inflammation, metabolism, and vascular health may also be connected to dementia risk.

Why This Matters for Dementia

Dementia is often thought of as a disease of the brain.

That is true, but incomplete.

The brain does not age in isolation. It depends on the health of blood vessels, metabolism, immune function, oxygen delivery, heart function, blood pressure, glucose regulation, sleep, inflammation control, and many other body-wide systems.

This is especially important for vascular dementia, which is closely linked to problems with blood flow to the brain. Stroke, small vessel disease, high blood pressure, diabetes, high cholesterol, and other cardiovascular factors can contribute to brain damage over time.

So it makes sense that a blood-based biological ageing clock would show a stronger connection with vascular dementia than with some other dementia subtypes.

If the body is ageing faster internally, the brain may be exposed to more vascular stress, metabolic strain, and inflammatory burden. Over years, those pressures may increase vulnerability to cognitive decline.

This is one of the most important lessons from the study:

Dementia risk is not only about memory.

It is also about whole-body health.

What the Study Found

Researchers at King’s College London analyzed data from more than 220,000 UK Biobank participants.

They examined blood plasma metabolites and used MileAge to estimate each person’s metabolomic or biological age. They then compared that biological age with chronological age and tracked dementia outcomes.

The results showed that people with accelerated biological ageing had a higher risk of developing dementia.

The association was especially strong for vascular dementia.

People whose biological age was significantly older than expected had around a 20% higher risk of all-cause dementia and around a 60% higher risk of vascular dementia.

The study also found that accelerated biological ageing was linked with earlier dementia onset.

The genetic-risk findings were even more striking. People who had both accelerated biological ageing and high genetic risk, especially those carrying two APOE ε4 alleles, had a much higher likelihood of developing dementia compared with the average participant.

This matters because it suggests biological ageing and genetic risk may capture different parts of the dementia-risk picture.

Genes may load the gun.

Biological ageing may show how much stress the body is carrying.

Together, they may help identify people who need closer attention long before symptoms begin.

Why Vascular Dementia Stood Out

One of the most interesting parts of the study is that the MileAge signal appeared particularly relevant for vascular dementia.

Vascular dementia happens when reduced blood flow damages the brain. It can follow a major stroke, but it can also develop gradually through small vessel damage, chronic high blood pressure, diabetes, cholesterol problems, smoking, heart disease, and other vascular risks.

Because MileAge is connected to metabolites involved in metabolism, lipids, inflammation, and cardiovascular health, it may be especially good at detecting body-wide ageing processes that affect blood vessels.

This is encouraging because vascular risk factors are often more modifiable than genetic risk.

You cannot change your inherited APOE status.

But many vascular and metabolic risks can be managed.

Blood pressure can be monitored.

Cholesterol can be treated.

Diabetes risk can be reduced.

Smoking can be stopped.

Physical activity can improve cardiovascular function.

Sleep can be protected.

Diet can support metabolic health.

Weight, inflammation, and heart health can often be improved.

This does not guarantee dementia prevention, but it gives doctors and patients something practical to work with.

If a blood-based biological ageing test can one day identify people with higher vascular dementia risk, it may help target prevention earlier, when intervention is more likely to matter.

The APOE4 Connection

APOE is a gene involved in lipid transport and brain biology.

One version of the gene, APOE ε4, is associated with higher risk of Alzheimer’s disease and dementia. A person can carry zero, one, or two copies of APOE ε4. Carrying two copies is linked with substantially higher genetic risk, although it still does not mean dementia is guaranteed.

The King’s College London study found that combining genetic risk with biological ageing information sharpened the risk picture.

People with both accelerated biological ageing and two APOE ε4 alleles had dramatically higher dementia risk compared with the study average.

This is important because it suggests future dementia-risk tools may become multi-layered.

Instead of relying on age alone, clinicians may eventually consider:

Chronological age.

Genetic risk.

Blood-based biological ageing.

Cardiovascular health.

Metabolic health.

Lifestyle factors.

Family history.

Cognitive changes.

Brain imaging or specialist biomarkers when appropriate.

That kind of layered approach could help identify who may benefit most from prevention strategies, closer monitoring, or clinical trials.

However, genetic risk information must be handled carefully. APOE testing can create anxiety, and it is not the same as a diagnosis. People should not interpret genetic risk without proper medical guidance.

Risk is not destiny.

Why This Is Not a Dementia Diagnosis

It is important to be very clear:

This study does not mean MileAge can diagnose dementia.

It does not mean a biological-age blood test can tell an individual with certainty whether they will develop dementia.

It does not mean the test is ready for routine public screening.

The study shows association and risk prediction in a large research dataset. That is valuable, but it is not the same as clinical validation for everyday medical use.

Before a test like this could become routine, researchers would need to answer several questions:

Does it work in more diverse populations?

Does it predict dementia accurately across different ethnic, socioeconomic, and geographic groups?

How does it perform compared with existing risk tools?

What cutoff should doctors use?

How often should people be tested?

Can lifestyle or medical interventions lower MileAge delta?

If MileAge improves, does dementia risk fall?

How should results be communicated without causing unnecessary fear?

Would testing improve outcomes, or simply label people as high risk?

These questions matter because screening is only useful if it leads to better care.

A test that predicts risk but does not change outcomes may create anxiety without benefit. A test that identifies modifiable risk and guides prevention could be much more useful.

That is why this research is promising, but still early.

Why Mid-Life May Be the Key Window

One of the most powerful ideas in dementia prevention is that risk builds long before symptoms appear.

Memory problems may emerge later in life, but the biological processes that contribute to dementia can begin decades earlier. Blood vessel damage, inflammation, insulin resistance, cholesterol problems, sleep disruption, hearing loss, depression, inactivity, smoking, and other factors may quietly shape brain vulnerability over time.

This makes mid-life a crucial window.

By the time dementia symptoms appear, the underlying damage may already be advanced. But in mid-life, there may be more opportunity to reduce risk.

A blood-based biological ageing tool could potentially help identify people whose bodies are ageing faster than expected before cognitive symptoms begin. That could shift the focus from late diagnosis to earlier prevention.

Instead of waiting for memory loss, doctors may one day be able to say:

Your biological ageing profile suggests higher long-term risk.

Let’s focus aggressively on blood pressure, cholesterol, exercise, sleep, diabetes prevention, smoking cessation, and brain-health habits now.

That kind of early warning could be valuable if it leads to action.

The key word is “if.”

A risk marker only matters clinically when it helps change the future.

The Role of Modifiable Risk Factors

One hopeful part of dementia science is that many risk factors are modifiable.

Not all dementia can be prevented. Genetics, age, and unknown biological processes still matter. But a significant portion of dementia risk appears connected to factors that can be reduced, delayed, or managed.

These include:

High blood pressure.

High LDL cholesterol.

Diabetes.

Smoking.

Obesity.

Physical inactivity.

Excessive alcohol use.

Hearing loss.

Vision loss.

Depression.

Social isolation.

Air pollution.

Low education.

Traumatic brain injury.

Poor cardiovascular health.

The MileAge study fits into this broader prevention picture because metabolomic ageing may capture biological traces of some modifiable risks.

For example, metabolites related to lipids, lipoproteins, amino acids, inflammation, and metabolism may reflect cardiovascular and metabolic health. If those systems are ageing faster, the brain may be at higher risk.

This does not mean people should blame themselves for dementia.

Dementia is complex. Many people live healthy lives and still develop it. Others have risk factors and never do.

The goal is not blame.

The goal is earlier awareness and better prevention.

What This Could Mean for Future Screening

If validated, a blood-based biological ageing test could eventually play several roles.

It could help identify people at higher dementia risk before symptoms begin.

It could help doctors prioritize prevention strategies for people with accelerated biological ageing.

It could help researchers select participants for dementia-prevention trials.

It could help track whether lifestyle or medical interventions are affecting biological ageing.

It could complement genetic information like APOE status.

It could support a more personalized approach to brain health.

But the future version of this test would need to be used responsibly.

A risk score should not become a sentence.

A person should not be told, “Your blood test says you will get dementia.”

That is not what the science supports.

A better approach would be:

Your blood profile suggests higher risk compared with people your age. Let’s use this information to strengthen prevention and monitoring.

That distinction matters.

The goal is empowerment, not fear.

Why “Simple Blood Test” Needs Careful Language

Headlines often love the phrase “simple blood test.”

It sounds clean, fast, and almost magical.

But blood tests are only simple at the moment of collection. The science behind them can be complex, and the interpretation can be even more complex.

A blood sample may be easy to draw, but a metabolomic ageing clock requires advanced analysis, statistical modeling, validation, and clinical interpretation. It must be accurate enough, reproducible enough, and useful enough to justify real-world use.

There is also the psychological side.

What happens if someone learns their biological age is older than their chronological age?

Will they feel motivated?

Will they feel anxious?

Will insurers, employers, or health systems misuse risk information?

Will people with fewer resources be blamed for accelerated ageing caused partly by poverty, pollution, stress, poor healthcare access, or unsafe environments?

These are not small questions.

The promise of biological-age testing is exciting, but it must be handled with scientific caution and ethical care.

The Difference Between Alzheimer’s and Vascular Dementia

Dementia is an umbrella term, not a single disease.

Alzheimer’s disease is the most widely known cause of dementia and is associated with amyloid and tau pathology in the brain.

Vascular dementia is linked to impaired blood flow and vascular damage.

There are also other forms, including Lewy body dementia, frontotemporal dementia, mixed dementia, and dementia associated with other diseases.

This distinction is important because the MileAge study showed particularly strong associations with vascular dementia and all-cause dementia, while the relationship with Alzheimer’s disease specifically was less clear in the fully adjusted analyses.

That does not make the findings less important.

In fact, it may make them more actionable.

Vascular dementia is closely tied to cardiovascular and metabolic health, areas where prevention and management can make a difference. A blood-based marker that helps identify vascular dementia risk may support earlier intervention around blood pressure, cholesterol, diabetes, heart health, and lifestyle.

Still, future research will need to clarify which dementia subtypes are most strongly predicted by metabolomic ageing and why.

What People Should Not Do

People should not treat this study as a reason to buy unvalidated biological-age tests online and panic over the results.

They should not assume a high biological age means dementia is inevitable.

They should not start supplements, medications, extreme diets, or anti-ageing treatments without medical guidance.

They should not interpret APOE status casually or without counseling.

They should not use biological age as a substitute for proper medical evaluation if symptoms are already present.

If someone is experiencing memory problems, confusion, personality changes, language difficulties, difficulty managing daily tasks, or other cognitive concerns, they should seek medical assessment rather than relying on wellness tests.

Biological-age testing may become part of the future.

But today, the best-supported steps for dementia risk reduction remain grounded in whole-body health.

What People Can Do Now

Even before tests like MileAge enter routine care, people can focus on known brain-health foundations.

Manage blood pressure.

Check cholesterol.

Stay physically active.

Avoid smoking.

Limit excessive alcohol.

Treat diabetes and metabolic risk.

Protect sleep.

Stay socially connected.

Treat hearing and vision problems.

Protect the head from injury.

Support mental health.

Eat a heart-healthy diet.

Keep learning and staying mentally engaged.

Discuss family history and risk factors with a clinician.

These steps are not glamorous, but they matter.

Brain health is built through everyday systems: blood flow, oxygen, movement, sleep, metabolism, connection, and resilience.

A future blood test may help identify who needs extra focus.

But the basic message is already clear:

What protects the heart often protects the brain.

Why This Study Feels Hopeful

Dementia can feel frightening because symptoms often appear after years of silent biological change.

Families may feel blindsided.

Patients may receive a diagnosis when options feel limited.

Doctors may struggle to identify who is at risk early enough to intervene.

This study offers a more hopeful possibility.

It suggests that subtle biological signals in the blood may reveal future risk before memory symptoms appear. It suggests that dementia risk may be connected to modifiable ageing pathways. It suggests that combining biological ageing with genetic risk could help identify people who need earlier prevention strategies.

That is not a cure.

It is not a guaranteed prediction.

But it is a step toward earlier, more personalized dementia prevention.

And in a disease area where timing matters deeply, earlier knowledge could one day make a real difference.

The Bigger Future of Ageing Clocks

Biological ageing clocks are becoming one of the most interesting areas of modern health research.

Scientists are exploring whether these clocks can predict risk for heart disease, diabetes, frailty, mortality, cognitive decline, and other age-related conditions. The long-term hope is that biological age may help move medicine from disease treatment to earlier risk detection and prevention.

But the field still needs caution.

Different ageing clocks measure different biological processes. A metabolomic clock is not the same as an epigenetic clock. A clock that predicts mortality may not be the best clock for dementia. A clock trained in one population may not work equally well in another.

The future will likely involve multiple biological clocks, each useful for different purposes.

For dementia, a metabolomic clock like MileAge may be valuable because it captures metabolic and vascular information relevant to brain health.

But it will need more validation before it becomes a routine medical tool.

Science moves forward through promising results, replication, refinement, and careful implementation.

This study is part of that journey.

Final Thoughts

The King’s College London study adds an important idea to dementia research:

The age of the body may help reveal the future risk of the brain.

By using a blood-based metabolomic ageing clock called MileAge, researchers found that people whose biological age was older than their chronological age had a higher risk of dementia, particularly vascular dementia. The risk was even greater when accelerated biological ageing was combined with high genetic risk.

The findings point toward a future where dementia prevention may become more personalized, more proactive, and more closely tied to whole-body health.

But the message must be balanced.

This is not a routine dementia test yet.

It is not a diagnosis.

It is not a certainty.

It is a promising research tool that may one day help identify people at higher risk before symptoms appear, guide prevention strategies, and improve clinical trial selection.

For now, the most practical lesson is simple:

Brain health begins long before memory problems.

It is shaped by blood vessels, metabolism, inflammation, genetics, lifestyle, environment, and time.

A blood test may one day help reveal who is ageing faster on the inside.

But the work of protecting the brain still begins with the body we care for today.

#DementiaResearch #BiologicalAge #BloodTest #MileAge #BrainHealth #VascularDementia #AlzheimersResearch #HealthyAging #Metabolomics #KingCollegeLondon #DementiaPrevention #APOE4

FAQs About Biological Age Blood Tests and Dementia Risk

What is biological age?

Biological age is an estimate of how old the body appears internally based on molecular, metabolic, or physiological markers. It can be higher or lower than chronological age.

What is MileAge?

MileAge is a metabolomic ageing clock that estimates biological age using metabolites found in blood plasma.

What did the King’s College London study find?

The study found that people whose biological age was older than their chronological age had a higher risk of dementia, especially vascular dementia, and tended to develop dementia earlier.

How many people were included in the study?

The study analyzed data from more than 220,000 UK Biobank participants.

What is MileAge delta?

MileAge delta is the difference between a person’s metabolomic biological age and their chronological age. A higher delta suggests accelerated biological ageing.

Does this blood test diagnose dementia?

No. The study suggests MileAge may help predict future dementia risk, but it is not currently a routine diagnostic test for dementia.

Why was vascular dementia strongly linked to biological ageing?

Vascular dementia is closely connected to blood vessel and cardiovascular health. Metabolomic ageing may capture biological signals related to metabolism, inflammation, and vascular risk.

What is APOE ε4?

APOE ε4 is a genetic variant associated with higher risk of Alzheimer’s disease and dementia. Carrying it increases risk but does not guarantee disease.

Can biological ageing be slowed?

Some factors linked to biological ageing may be modifiable, including blood pressure, cholesterol, physical activity, smoking, diabetes risk, sleep, and cardiovascular health. More research is needed to know whether lowering biological age directly reduces dementia risk.

Should people get biological age testing now?

Routine biological-age testing for dementia prediction is not yet established. Anyone concerned about dementia risk, memory changes, or family history should speak with a qualified healthcare professional.